{
    "nctId": "NCT04067726",
    "briefTitle": "RANKL Inhibition and Mammographic Breast Density",
    "officialTitle": "Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Dense Breasts",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 210,
    "primaryOutcomeMeasure": "Change in mammographic breast density between the two arms as measured by volumetric percent density",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female.\n* Premenopausal (when menopausal status is uncertain, the investigators will measure follicle-stimulating hormone and estradiol to ascertain that a partcipant is premenopausal)\n* At least 40 years of age.\n* Dense breasts on routine mammogram (BI-RADS Category C and D)\n* Able to understand and willing to sign an IRB-approved written informed consent document.\n\nExclusion Criteria:\n\n* History of breast or any other invasive cancer except for DCIS (ductal carcinoma in situ) who received only lumpectomy, LCIS (lobular carcinoma in situ), atypical hyperplasia, non-melanoma skin cancer, carcinoma in situ of the cervix.\n* Current use of tamoxifen, aromatase inhibitors, or bisphosphonates, or RANKL inhibitors\n* Concurrent participation in another cancer chemoprevention trial (unless no longer receiving the intervention).\n* Pregnant, lactating, or planning to get pregnant while the trial is ongoing.\n* Recent history of invasive dental procedure (e.g. tooth extraction, dental implant, oral surgery).\n* Unhealed and/or planned dental/oral surgery.\n* History of osteonecrosis/osteomyelitis of the jaw.\n* History of osteoporosis or severe osteopenia.",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}